Context Therapeutics Inc (CNTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has a cash flow conversion efficiency ratio of -0.184x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.02 Million) by net assets ($38.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Context Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Context Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Context Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Context Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Context Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Context Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Urbanfund Corp
V:UFC
|
0.028x |
|
ALPHA EXPLORATION LTD
F:J0C
|
-0.010x |
|
Carnival PLC
LSE:CCL
|
0.096x |
|
Mabion S.A.
WAR:MAB
|
-0.308x |
|
Metallic Minerals Corp
V:MMG
|
-0.327x |
|
Baird Medical Investment Holdings Limited
NASDAQ:BDMD
|
-0.090x |
|
A-Tech Solution Co. Ltd
KQ:071670
|
-0.090x |
|
Far East Gold Ltd
AU:FEG
|
-0.093x |
Annual Cash Flow Conversion Efficiency for Context Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2025. View CNTX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $60.47 Million | $-26.39 Million | -0.436x | -185.56% |
| 2024-12-31 | $95.27 Million | $-14.56 Million | -0.153x | +91.38% |
| 2023-12-31 | $11.87 Million | $-21.05 Million | -1.773x | -354.84% |
| 2022-12-31 | $34.76 Million | $-13.55 Million | -0.390x | -113.84% |
| 2021-12-31 | $48.27 Million | $-8.80 Million | -0.182x | -398.13% |
| 2020-12-31 | $-16.92 Million | $-1.03 Million | 0.061x | -48.34% |
| 2019-12-31 | $-23.96 Million | $-2.84 Million | 0.118x | +131.22% |
| 2017-12-31 | $58.95 Million | $-22.35 Million | -0.379x | +83.73% |
| 2016-12-31 | $13.12 Million | $-30.57 Million | -2.331x | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more